Katherine A. Pratte

Katherine A. Pratte

Auto-generated profile, based on publicly available information

Katherine A. Pratte

Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO 80206, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2019 in Metabolites
Verified
Journal Article
Open access
EHEitan Halper-Stromberg
Eitan Halper-Stromberg
LGLucas Gillenwater
Lucas Gillenwater
CCCharmion Cruickshank-Quinn
Charmion Cruickshank-Quinn
WOWanda Kay O’nEal
Wanda Kay O’nEal
NRNichole Reisdorph
Nichole Reisdorph
RBRussell P. Bowler
Russell P. Bowler
Smoking causes chronic obstructive pulmonary disease (COPD). Though recent studies identified a COPD metabolomic signature in blood, no large studies examine the metabolome in bronchoalveolar lavage (BAL) fluid, a more direct representation of lung cell metabolism. We performed untargeted liquid chromatography–mass spectrometry (LC–MS) on BAL and matched plasma from 115 subjects from the SPIROMICS cohort. Regression was performed with COPD phenotypes as the outcome and metabolites as the predictor, adjusted for clinical covariates and false discovery rate. Weighted gene co-expression network analysis (WGCNA) grouped metabolites into modules which were then associated with phenotypes. K-means clustering grouped similar subjects. We detected 7939 and 10,561 compounds in BAL and paired plasma samples, respectively. FEV1/FVC (Forced Expiratory Volume in One Second/Forced Vital Capacity) ratio, emphysema, FEV1 % predicted, and COPD exacerbations associated with 1230, 792, eight, and one BAL compounds, respectively. Only two plasma compounds associated with a COPD phenotype (emphysema). Three BAL co-expression modules associated with FEV1/FVC and emphysema. K-means BAL metabolomic signature clustering identified two groups, one with more airway obstruction (34% of subjects, median FEV1/FVC 0.67), one with less (66% of subjects, median FEV1/FVC 0.77; p < 2 × 10−4). Associations between metabolites and COPD phenotypes are more robustly represented in BAL compared to plasma.

7 July 2020 in Radiology
Verified
Journal Article
Closed access
AOAndrea S. Oh
Andrea S. Oh
MSMatthew Strand
Matthew Strand
KPKatherine Pratte
Katherine Pratte
ERElizabeth A. Regan
Elizabeth A. Regan
SHStephen Humphries
Stephen Humphries
FIFor the Genetic Epidemiology of COPDGene Investigators
For the Genetic Epidemiology of COPDGene Investigators
The presence of visually evident emphysema on CT images in smokers with normal spirometry, labeled as GOLD stage 0, had progressive airflow obstruction and progression of emphysema over 5 years. Background The clinical significance of visually evident emphysema on CT images in individuals without spirometric evidence of chronic obstructive pulmonary disease (COPD) by current diagnostic cri...

25 March 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
EMEmily Mastej
Emily Mastej
LGLucas Gillenwater
Lucas Gillenwater
YZYonghua Zhuang
Yonghua Zhuang
KPKatherine A. Pratte
Katherine A. Pratte
RBRussell P. Bowler
Russell P. Bowler
KKKaterina Kechris
Katerina Kechris
Chronic obstructive pulmonary disease (COPD) is a disease in which airflow obstruction in the lung makes it difficult for patients to breathe. Although COPD occurs predominantly in smokers, there are still deficits in our understanding of the additional risk factors in smokers. To gain a deeper understanding of the COPD molecular signatures, we used Sparse Multiple Canonical Correlation Network (SmCCNet), a recently developed tool that uses sparse multiple canonical correlation analysis, to integrate proteomic and metabolomic data from the blood of 1008 participants of the COPDGene study to identify novel protein–metabolite networks associated with lung function and emphysema. Our aim was to integrate -omic data through SmCCNet to build interpretable networks that could assist in the discovery of novel biomarkers that may have been overlooked in alternative biomarker discovery methods. We found a protein–metabolite network consisting of 13 proteins and 7 metabolites which had a −0.34 correlation (p-value = 2.5 × 10−28) to lung function. We also found a network of 13 proteins and 10 metabolites that had a −0.27 correlation (p-value = 2.6 × 10−17) to percent emphysema. Protein–metabolite networks can provide additional information on the progression of COPD that complements single biomarker or single -omic analyses.

11 March 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
LGLucas A. Gillenwater
Lucas A. Gillenwater
KKKaterina Kechris
Katerina Kechris
KPKatherine A. Pratte
Katherine A. Pratte
NRNichole Reisdorph
Nichole Reisdorph
IPIrina Petrache
Irina Petrache
RBRussell P. Bowler
Russell P. Bowler
Susceptibility and progression of lung disease, as well as response to treatment, often differ by sex, yet the metabolic mechanisms driving these sex-specific differences are still poorly understood. Women with chronic obstructive pulmonary disease (COPD) have less emphysema and more small airway disease on average than men, though these differences become less pronounced with more severe airflow limitation. While small studies of targeted metabolites have identified compounds differing by sex and COPD status, the sex-specific effect of COPD on systemic metabolism has yet to be interrogated. Significant sex differences were observed in 9 of the 11 modules identified in COPDGene. Sex-specific associations by COPD status and emphysema were observed in 3 modules for each phenotype. Sex stratified individual metabolite associations with COPD demonstrated male-specific associations in sphingomyelins and female-specific associations in acyl carnitines and phosphatidylethanolamines. There was high preservation of module assignments in SPIROMICS (SubPopulations and InteRmediate Outcome Measures In COPD Study) and similar female-specific shift in acyl carnitines. Several COPD associated metabolites differed by sex. Acyl carnitines and sphingomyelins demonstrate sex-specific abundances and may represent important metabolic signatures of sex differences in COPD. Accurately characterizing the sex-specific molecular differences in COPD is vital for personalized diagnostics and therapeutics.

19 April 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
SGSuneeta Vishnu Godbole
Suneeta Vishnu Godbole
WLWassim W. Labaki
Wassim W. Labaki
KPKatherine A. Pratte
Katherine A. Pratte
AHAndrew Hill
Andrew Hill
MMMatthew Moll
Matthew Moll
RBRussell P. Bowler
Russell P. Bowler
Chronic obstructive pulmonary disease (COPD) is a disease with marked metabolic disturbance. Previous studies have shown the association between single metabolites and lung function for COPD, but whether a combination of metabolites could predict phenotype is unknown. We developed metabolomic severity scores using plasma metabolomics from the Metabolon platform from two US cohorts of ever-smokers: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) (n = 648; training/testing cohort; 72% non-Hispanic, white; average age 63 years) and the COPDGene Study (n = 1120; validation cohort; 92% non-Hispanic, white; average age 67 years). Separate adaptive LASSO (adaLASSO) models were used to model forced expiratory volume at one second (FEV1) and MESA-adjusted lung density using 762 metabolites common between studies. Metabolite coefficients selected by the adaLASSO procedure were used to create a metabolomic severity score (metSS) for each outcome. A total of 132 metabolites were selected to create a metSS for FEV1. The metSS-only models explained 64.8% and 31.7% of the variability in FEV1 in the training and validation cohorts, respectively. For MESA-adjusted lung density, 129 metabolites were selected, and metSS-only models explained 59.0% of the variability in the training cohort and 17.4% in the validation cohort. Regression models including both clinical covariates and the metSS explained more variability than either the clinical covariate or metSS-only models (53.4% vs. 46.4% and 31.6%) in the validation dataset. The metabolomic pathways for arginine biosynthesis; aminoacyl-tRNA biosynthesis; and glycine, serine, and threonine pathway were enriched by adaLASSO metabolites for FEV1. This is the first demonstration of a respiratory metabolomic severity score, which shows how a metSS can add explanation of variance to clinical predictors of FEV1 and MESA-adjusted lung density. The advantage of a comprehensive metSS is that it explains more disease than individual metabolites and can account for substantial collinearity among classes of metabolites. Future studies should be performed to determine whether metSSs are similar in younger, and more racially and ethnically diverse populations as well as whether a metabolomic severity score can predict disease development in individuals who do not yet have COPD.

7 June 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AHAndrew C. Hill
Andrew C. Hill
CGClaire Guo
Claire Guo
ELElizabeth M. Litkowski
Elizabeth M. Litkowski
AMAni Manichaikul
Ani Manichaikul
BYBing Yu
Bing Yu
RBRussell P. Bowler
Russell P. Bowler
Privacy protection is a core principle of genomic but not proteomic research. We identified independent single nucleotide polymorphism (SNP) quantitative trait loci (pQTL) from COPDGene and Jackson Heart Study (JHS), calculated continuous protein level genotype probabilities, and then applied a naïve Bayesian approach to link SomaScan 1.3K proteomes to genomes for 2812 independent subjects from COPDGene, JHS, SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) and Multi-Ethnic Study of Atherosclerosis (MESA). We correctly linked 90–95% of proteomes to their correct genome and for 95–99% we identify the 1% most likely links. The linking accuracy in subjects with African ancestry was lower (~ 60%) unless training included diverse subjects. With larger profiling (SomaScan 5K) in the Atherosclerosis Risk Communities (ARIC) correct identification was > 99% even in mixed ancestry populations. We also linked proteomes-to-proteomes and used the proteome only to determine features such as sex, ancestry, and first-degree relatives. When serial proteomes are available, the linking algorithm can be used to identify and correct mislabeled samples. This work also demonstrates the importance of including diverse populations in omics research and that large proteomic datasets (> 1000 proteins) can be accurately linked to a specific genome through pQTL knowledge and should not be considered unidentifiable.